Back to News
Market Impact: 0.15
Immuron Reports Phase 2 Travelan Results Published In Scientific Reports; Stock Down
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Immuron Limited announced that results from a Phase 2 trial evaluating once-daily oral Travelan for preventing travelers’ diarrhea were published in Scientific Reports. The article excerpt provides no trial outcome figures or efficacy details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
IMRN0.35
More News
- South Korean carmaker Hyundai plans 'strategic' investment of $15.5 billion in India by 2032
- Applied Materials’ $5 billion AI lab aims to cut chip development time in half—and restore Silicon Valley’s edge
- Wells Fargo CFO on Earnings, Deals, Consumer Strength
- Bank of America hit with more than $1.2 billion in penalties over money-laundering violations
- Meta’s Muse models reach the AI frontier—and kill any hopes to ‘pace’ it
- We're upgrading our Goldman Sachs rating after a strong quarter bodes well for the future